Skip to main content
Clinical Trials/EUCTR2022-000161-40-AT
EUCTR2022-000161-40-AT
Active, Not Recruiting
Phase 1

Investigating cardiometabolic risk factors and changes in chronobiology patterns in patients with autonomous adrenal cortisol secretion

Medical University of Vienna, Division of Endocrinology0 sites50 target enrollmentJune 8, 2022

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Not specified
Sponsor
Medical University of Vienna, Division of Endocrinology
Enrollment
50
Status
Active, Not Recruiting
Last Updated
3 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
June 8, 2022
End Date
TBD
Last Updated
3 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Sponsor
Medical University of Vienna, Division of Endocrinology

Eligibility Criteria

Inclusion Criteria

  • For patients with autonomous cortisol secretion:
  • i) morning cortisol \> 5 ug/dl following 1 mg dexamethasone suppression test or ii) cortisol 1,8\-5 ug/dl following 1 mg dexamethasone suppression test with a low morning ACTH concentration (ACTH \< 10 pg/ml), without classical clinical features associated with the presence of Cushing’s syndrome.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1\.2 Adults (18\-64 years) yes
  • F.1\.2\.1 Number of subjects for this age range 40
  • F.1\.3 Elderly (\>\=65 years) yes
  • F.1\.3\.1 Number of subjects for this age range 10

Exclusion Criteria

  • HbA1c \> 7 % and/or treatment with other anti\-diabetics than metformin and/or DPP\-IV inhibitors
  • uncontrolled hypertension (RR \> 170/110 mmHg; treatment with no more than 3 antihypertensive drugs)
  • previous treatment with glucocorticoids within the last 3 months
  • concomitant treatment with drugs affecting HPA signaling or CYP3A4 metabolism
  • adrenal tumor with radiological criteria suspicious for malignancy
  • chronic kidney disease (eGFR \< 45 ml/min)
  • liver disease (ASAT / ALAT \> 3 x ULN)
  • pregnancy or breast feeding
  • general MR contraindications (claustrophobia, metal devices or other magnetic material in the body which will be hazardous for MR investigation

Outcomes

Primary Outcomes

Not specified

Similar Trials